Takeda Highlights Arcotatug and TAK-928 at ESMO 2026
OSAKA, Japan and CAMBRIDGE, Mass. — September 22, 2026 Takeda announced that new data from its oncology pipeline and...
Gastric Cancer
Advertisement
Jazz Reports Survival Benefit for Ziihera in GEA
Dublin, Ireland, August 31, 2026 Jazz Pharmaceuticals plc announced positive topline results from the Phase 3 HERIZON-GEA-01 clinical trial,...
BeOne Reports New Phase 3 Survival Data for ZIIHERA
San Carlos, Calif. – August 31, 2026 BeOne Medicines announced new Phase 3 overall survival data from the HERIZON-GEA-01...
Jazz Pharmaceuticals Gains FDA Approval for HER2+ GEA
Dublin, Ireland, August 25, 2026 Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved two...
BeOne Wins FDA Approval for TEVIMBRA HER2+ GEA Regimen
SAN CARLOS, Calif., August 25, 2026 BeOne Medicines Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
Aravax Wins FDA Fast Track Designation for PVX108
MELBOURNE, Australia & OXFORD, UK, Aug. 3, 2026 Aravax announced that the U.S. Food and Drug Administration (FDA) has...
IMPACT Therapeutics Names IMP3201 First Dual-Payload ADC Candidate
SHANGHAI, China, July 27, 2026 IMPACT Therapeutics announced the nomination of IMP3201 as a preclinical candidate (PCC), marking the...
Iksuda Therapeutics Secures FDA IND Clearance for IKS04
Newcastle, UK, July 30, 2026 Iksuda Therapeutics has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)...
Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials
CHENGDU, China, July 27, 2026 Kelun-Biotech has announced that the Center for Drug Evaluation (CDE) of China’s National Medical...
AstraZeneca’s Sone-Ve Delivers Phase III Survival Breakthrough
CAMBRIDGE, UK, July 27, 2026 AstraZeneca has announced positive high-level results from the global Phase III CLARITY-Gastric01 trial, demonstrating...
Advertisement
